Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology (ASCO). The data relate to completed and ongoing clinical trials of JX-594 in lead indication, hepatocellular carcinoma (liver cancer), as well as in colorectal cancer where JX-594 was administered via multiple intravenous infusions. The ASCO Annual Meeting takes place June 1st through 5th, 2012 in Chicago, Illinois.
Following is information relating to the three abstracts:
- Abstract #TPS4152: " Phase IIb randomized trial of JX-594, a targeted multi-mechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)." Poster to be presented in S Hall A2 on June 4, 2012, 8:00 a.m. – 12:00 p.m. CDT, in the General Poster Session: Gastrointestinal (Noncolorectal) Cancer.
- Abstract #e14566: " A phase II trial of JX-594, a targeted multi-mechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)." Abstract available on ASCO website only (http://chicago2012.asco.org/Home.aspx)
- Abstract #e13044: "A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma." Abstract available on ASCO website only (http://chicago2012.asco.org/Home.aspx).